REG - C4X Discovery - Result of AGM

C4X Discovery HoldingsAnnouncement

19/01/2021 14:30

RNS Number : 2085M
  
C4X Discovery Holdings PLC
  
19 January 2021
  
 

C4X Discovery Holdings plc
 
("C4XD", "C4X Discovery" or the "Company")
 
Results of AGM
 
 
19 January 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that at its Annual General Meeting, held virtually today at 2.00 pm, all resolutions were duly passed.
 
- Ends -
 
Contacts
 



C4X Discovery Holdings








Mo Noonan, Communications


+44 (0)787 6444977














Panmure Gordon (UK) Limited (NOMAD and Broker) 








Freddy Crossley, Emma Earl (Corporate Finance)


+44 (0)20 7886 2500




Rupert Dearden (Corporate Broking)


















C4X Discovery Media - Consilium Strategic Communications








Mary-Jane Elliott, Chris Gardner, Matthew Neal


+44 (0)203 709 5700



 
Notes to Editors:
 
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study.
 
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
 
For additional information please go to: www.c4xdiscovery.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGBSGDBRDBDGBC